Helen Phillips
Corporate Officer/Principal at AMRYT PHARMA PLC
Profile
Helen Phillips is currently the Head of Medical Affairs at Amryt Pharma Plc.
Prior to this, she held the position of Medical Director-EMEA at Aegerion Pharmaceuticals, Inc. and was also the Head of Medical Affairs at Amryt Pharma Holdings Ltd.
She completed her undergraduate degree at the University of Bristol.
Helen Phillips active positions
Companies | Position | Start |
---|---|---|
AMRYT PHARMA PLC | Corporate Officer/Principal | - |
Former positions of Helen Phillips
Companies | Position | End |
---|---|---|
AEGERION PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | - |
Training of Helen Phillips
University of Bristol | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 3 |
---|---|
Aegerion Pharmaceuticals, Inc.
Aegerion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aegerion Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development and commercialization of therapies for patients with debilitating rare diseases. The company was founded by David I. Scheer, Gerald L. Wisler and William H. Lewis in 2005 and is headquartered in Cambridge, MA. | Health Technology |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | Health Technology |
Amryt Pharma Plc
Amryt Pharma Plc Pharmaceuticals: MajorHealth Technology Amryt Pharma Plc operates as a holding company with interests in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. The company was founded on July 17, 2019 and is headquartered in Dublin, Ireland. | Health Technology |
- Stock Market
- Insiders
- Helen Phillips